Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof

A Parkinson's disease and composition technology, applied in the field of pharmaceutical compositions, can solve the problems of Parkinson's disease that have not yet been seen, and achieve the effects of prevention and treatment of Parkinson's disease, easy quality control, and simple preparation process

Active Publication Date: 2009-09-23
HAERBIN SHENGYUAN BIOENG
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, Acanthopanax compound and Acanthopanax injection have been used in the clinical treatment of Parkinson's disease, and have achieved certain curative effect, but so far, there has been no study of the active ingredients of Acanthopanax senticosus in the treatment of Parkinson's disease. Therefore, the ratio of active ingredients of Acanthopanax senticosus to treat Parkinson's disease has broad market development prospects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof
  • Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof
  • Pharmaceutical composition for preventing or treating parkinsonism and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0018] 1. Experimental cell line: Shanghai Cell Institute, Chinese Academy of Sciences

[0019] 2. Experimental drug: MPP+ SIGMA-RBI company

[0020] Eleutheroside B standard

[0021] 3. Experimental method: make PC12 cells into a single cell suspension, and use 5×10 4 / ml inoculated in 96-well culture plate. After continuous culture for 24 hours, the medium was changed, and different concentrations of eleutheroside B dilutions were added to each well, so that the final concentrations were 2.5, 5, 10, 20, 40, and 80 μg / ml, and the final concentrations were added at the same time. 300μmol / L MPP + solution. After further culturing for 48 hours, 20 μl of MTT solution (5 mg / ml) was added to each well, and incubated at 37° C. for 4 hours. After terminating the culture, carefully suck out the medium, add 150 μl DMSO to each well, and shake for 10 minutes to fully dissolve the crystals. The absorbance value of each well at 490nm was detected by a microplate reader,...

experiment example 2

[0030] 1. Experimental cell line: Shanghai Cell Institute, Chinese Academy of Sciences

[0031] 2. Experimental drug: MPP+ SIGMA-RBI company

[0032] Eleutheroside D standard

[0033] 3. Experimental method: make PC12 cells into a single cell suspension, and use 5×10 4 / ml inoculated in 96-well culture plate. After continuous culture for 24 hours, the medium was changed, and different concentrations of eleutheroside D dilutions were added to each well so that the final concentrations were 2.5, 5, 10, 20, 40, and 80 μg / ml, and the final concentrations were added at the same time. 300μmol / L MPP + solution. After further culturing for 48 hours, 20 μl of MTT solution (5 mg / ml) was added to each well, and incubated at 37° C. for 4 hours. After terminating the culture, carefully suck out the medium, add 150 μl DMSO to each well, and shake for 10 minutes to fully dissolve the crystals. The absorbance value of each well at 490nm was detected by a microplate reader, ...

experiment example 3

[0043] 1. Experimental cell line: Shanghai Cell Institute, Chinese Academy of Sciences

[0044] 2. Experimental drug: MPP+ SIGMA-RBI company

[0045] Eugenol diglucoside

[0046] 3. Experimental method: make PC12 cells into a single cell suspension, and use 5×10 4 / ml inoculated in 96-well culture plate. After continuous culture for 24 hours, the medium was changed, and different concentrations of eugenol diglucoside dilutions were added to each well, so that the final concentrations were 2.5, 5, 10, 20, 40, and 80 μg / ml. Concentration 300μmol / L MPP + solution. After further culturing for 48 hours, 20 μl of MTT solution (5 mg / ml) was added to each well, and incubated at 37° C. for 4 hours. After terminating the culture, carefully suck out the medium, add 150 μl DMSO to each well, and shake for 10 minutes to fully dissolve the crystals. The absorbance value of each well at 490nm was detected by a microplate reader, and the cell viability was calculated. The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition for preventing or treating parkinsonism and a preparation method thereof. The pharmaceutical composition consists of eleutheroside B, eleutheroside D, syringaresinol-di-glucoside and daucosterol. The invention determines the optimal dose level range of the four components and on the base, adopts an orthogonal test for screening out the optimal compatibility proportion of the four active components. Proved by experiment results, the pharmaceutical composition which is prepared by the compatibility of the eleutheroside B, the eleutheroside D, the syringaresinol-di-glucoside and the daucosterol according to a weight ratio of 1:2:8:8, can obviously improve PC12 cell survival rate and has obvious protective effects on dopaminergic neuron injuries. The active ingredients of the acanthopanax have simple and clear chemical compositions and quality control is easy to be conducted in production. The pharmaceutical composition can be used for preparing medicaments with good therapeutic effects for preventing and treating parkinsonism safely and reliably.

Description

technical field [0001] The present invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition composed of the active ingredients of Acanthopanax senticosus according to a specific ratio. The present invention also relates to the use of the pharmaceutical composition in the prevention or treatment of Parkinson's disease, which belongs to Parkinson's disease. Therapeutic areas for Kinson's disease. Background technique [0002] Parkinson's disease (PD) is a common degenerative disease of the central nervous system, and its incidence increases with age. There are currently 1.7 million PD patients in my country, and the number is increasing at an annual rate of 100,000. Because the disease seriously affects the patient's activity ability and quality of life, the disability rate is high, the course of the disease is long, and often requires life-long treatment, thus bringing serious social and economic burdens to mankind. Therefore, there i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K31/7034A61K31/704A61P25/16
Inventor 刘树民卢芳安丽凤杨婷婷
Owner HAERBIN SHENGYUAN BIOENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com